Table 2.
Effect on liver | Site of action | Chemical involved | Mechanisms |
---|---|---|---|
Antifibrotic | Hepatic Stellate Cell (HSC) | Caffeine | Inhibit focal adhesion kinase (FAK) and actin synthesis |
Increase HSC apoptosis and intracellular F-actin and cAMP expression | |||
Inhibit procollagen type 1C and alpha-SMA expression | |||
Hepatocyte | Caffeine | Decrease transforming growth factor beta (TGF-B) | |
Stimulate ARE-regulated signaling | |||
Cancer prevention | Hepatocyte | Cafestol and Kehweol | Inhibit phase I activating enzyme expression and activity |
Induce phase II detoxifying enzymes (i.e. glutathione S-transferase) | |||
Stimulate antioxidant responsive element (ARE)-regulated signaling | |||
Induction of gamma-glutamyl cysteine synthetase (GCS) | |||
Antioxidant effect | Hepatocytes | Hydrophilic (caffeine and polyphenols, such as chlorogenic acids); hydrophobic (cafestol, kahweol, and trigenolline), including MRP | Preventing inflammatory reaction downregulation of immune and inflammatory markers, such as interferon-gamma (IFN-γ), chemokine coded by CX3CL1 or fractalkine, chemokine ligand4 or CCL4 also called macrophage inhibitory protein (MIP-1b), fibroblast growth factor-2 (FGF-2), and tumor necrosis factor receptors (sTNFRII) |
Modified from Saab et al.77